

Adaptimmune Therapeutics PLC  
Form 6-K  
September 15, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of September, 2015

Commission File Number: 001-37368

---

**ADAPTIMMUNE THERAPEUTICS PLC**

(Translation of registrant's name into English)

---

101 Park Drive, Milton Park  
Abingdon, Oxfordshire OX14 4RY  
United Kingdom

## Edgar Filing: Adaptimmune Therapeutics PLC - Form 6-K

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

**Other Events**

On September 14, 2015, Adaptimmune Therapeutics plc (the Company) issued a press release announcing that on September 17, 2015, James Noble, the Company's Chief Executive Officer, will be presenting at the 2015 Morgan Stanley Global Healthcare Conference and Dr. Helen Tayton-Martin, the Company's Chief Operating Officer, will be presenting at the 2015 Bank of America Merrill Lynch Global Healthcare Conference. The press release is attached as Exhibit 99.1 and the presentation to be given at the 2015 Morgan Stanley Global Healthcare Conference is attached as Exhibit 99.2 and both exhibits are incorporated by reference herein. A shortened version of Exhibit 99.2 will be presented at the 2015 Bank of America Merrill Lynch Global Healthcare Conference.

**Exhibits**

99.1 Press release dated September 14, 2015

99.2 Presentation materials dated September 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Adaptimmune Therapeutics plc**

By:	/s/ Margaret Henry
Name:	Margaret Henry
Title:	Corporate Secretary

Date: September 15, 2015